ArticleBioscience reports2020
Explore prognostic biomarker of bladder cancer based on competing endogenous network.
Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 12 citations in OpenAlex.
- LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.World journal of surgical oncology · 2026Article
- Potential prognostic biomarkers in restenosis of peripheral arteries identified through comprehensive ceRNA network analysis.Frontiers in genetics · 2025Article
- Identification of S100A9 as a Potential Inflammation-Related Biomarker for Radiation-Induced Lung Injury.Journal of clinical medicine · 2023Article
- Application of Protein-Protein Interaction Network Analysis in Order to Identify Cervical Cancer miRNA and mRNA Biomarkers.TheScientificWorldJournal · 2023Article
- LncRNA GAS5 regulates the Wnt/β-catenin pathway through the miR-18a-5p/AXIN2/GSK3β axis to inhibit the proliferation and migration of bladder cancer cells.Carcinogenesis · 2022Article
- Integrated Analysis of ceRNA Network to Reveal Potential Prognostic Biomarkers for Glioblastoma.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BC) is the most common tumor of the urinary tract. Increasing evidence showed that long non-coding RNA (lncRNA) is a critical regulator in cancer development and progression. However, the functions of lncRNAs in the development of BC remain mostly undefined. In the present study, based on RNA sequence profiles from The Cancer Genome Atlas database, we identified 723 lncRNAs, 157 miRNAs, and 1816 mRNAs aberrantly expressed in BC tissues. A competing endogenous RNA network, including 49 lncRNAs, 17 miRNAs, and 36 mRNAs, was then established. The functional enrichment analyses showed that the mRNAs in the ceRNA network mainly participated in 'regulation of transcription' and 'pathways in cancer'. Moreover, the Cox regression analyses demonstrated that three lncRNAs (AC112721.1, TMPRSS11GP, and ADAMTS9-AS1) could serve as independent risk factors. We established a risk prediction model with these lncRNAs. Kaplan-Meier curve analysis showed that high-risk patients' prognosis was lower than that of low-risk patients (P=0.001). The present study provides novel insights into the lncRNA-mediated ceRNA network and the potential of lncRNAs to be candidate prognostic biomarkers in BC, which could help better understand the pathological changes and pathogenesis of BC and be useful for clinical studies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.